UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2024
BIO-TECHNE CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Minnesota | 0-17272 | 41-1427402 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
55413 |
614 McKinley Place NE Minneapolis, Minnesota 55413 |
(Address of Principal Executive Offices) (Zip Code) |
|
(612) 379-8854 |
(Registrant’s Telephone Number, Including Area Code) |
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock | TECH | NASDAQ |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 30, 2024, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) granted James Hippel, the Company’s Executive Vice President, Chief Financial Officer, a one-time restricted stock unit award in the amount of 34,634 shares pursuant to the Company’s 2020 Equity Incentive Plan, as amended to date (the “Plan”). The restricted stock unit award will vest in equal installments on the first three anniversaries of the grant date, subject to Mr. Hippel’s continued service with the Company and the terms of the Plan and the underlying award agreement. The restricted stock unit award was granted for purposes of retention and after considering stock options that Mr. Hippel forfeited due to a stock plan administrative error in recording the expiration date.
Item 9.01. Financial Statements and Exhibits
Exhibit No. | Description |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| |
| |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIO-TECHNE CORPORATION |
| |
|
|
|
|
Date: November 5, 2024 | By: | /s/ Shane V. Bohnen |
|
| Shane V. Bohnen |
| |
| Senior Vice President, General Counsel and Corporate Secretary | ||
